0.57
+0.023(+4.19%)
Currency In USD
| Previous Close | 0.55 |
| Open | 0.57 |
| Day High | 0.58 |
| Day Low | 0.55 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 1.48M |
| Average Volume | 13.8M |
| Market Cap | 34.59M |
| PE | -0.6 |
| EPS | -0.96 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 0.58 |
| Change | 0.02 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.03 as of December 25, 2025 at a share price of $0.572. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $16.29 as of December 25, 2025 at a share price of $0.572.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Expands CNSide Assay Platform to State of California
GlobeNewswire Inc.
Dec 11, 2025 12:30 PM GMT
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Compan
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
GlobeNewswire Inc.
Dec 09, 2025 12:30 PM GMT
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syste
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
GlobeNewswire Inc.
Dec 04, 2025 12:30 PM GMT
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal,